PharmiWeb

ADC Therapeutics Presents Updated Clinical Data at 2021 ASCO Annual Meeting

ZYNLONTA™ LOTIS-2 updated data includes median duration of response of 13.4 months in heavily pre-treated patients with relapsed or refractory DLBCL Subgroup analyses include patients with double- / ...
Business Wire

ADC Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted ...
PharmiWeb

ADC Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

ADC Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates ZYNLONTA ® (loncastuximab tesirine-lpyl) net sales of $17.0 million in the fourth quarter of ...
Seeking Alpha

ADC Therapeutics SA (ADCT) CEO Christopher Martin on Q4 2021 Results - Earnings Call Transcript

Welcome to the ADC Therapeutics Fourth Quarter and Year End 2021 Financial Results Conference Call. My name is Josh and I will be your operator for today's call. At this time, all participants are in ...
The Motley Fool

ADC Therapeutics SA (ADCT) Q1 2021 Earnings Call Transcript

Good morning, and welcome to the ADC Therapeutics first-quarter results 2021 financial call. My name is Cheryl, and I will be your operator for today's call. [Operator instructions] I will now turn ...
Yahoo Finance

ADC Cytotoxic Payloads / Warheads: Products and Services Market, 2021-2035

New York, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "ADC Cytotoxic Payloads / Warheads: Products and Services Market ...